Capital World Investors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Capital World Investors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-683,000	Closed	-$13.7M	–	534
2023 Q3	$13.7M	Hold	683,000	–	–	﹤0.01%	460
2023 Q2	$19.3M	Hold	683,000	–	–	﹤0.01%	441
2023 Q1	$11.7M	Hold	683,000	–	–	﹤0.01%	463
2022 Q4	$13.8M	Hold	683,000	–	–	﹤0.01%	475
2022 Q3	$14.8M	Hold	683,000	–	–	﹤0.01%	475
2022 Q2	$19.2M	Hold	683,000	–	–	﹤0.01%	463
2022 Q1	$31.5M	Hold	683,000	–	–	0.01%	461
2021 Q4	$57.4M	Hold	683,000	–	–	0.01%	430
2021 Q3	$45.5M	Buy	683,000 +13,000	+2%	+$750K	0.01%	455
2021 Q2	$35.6M	Buy	670,000 +300,000	+81%	+$16.1M	0.01%	484
2021 Q1	$16.1M	Sell	370,000 -480,000	-56%	-$20.7M	﹤0.01%	528
2020 Q4	$44.1M	Buy	850,000 +186,000	+28%	+$8.39M	0.01%	422
2020 Q3	$21.7M	Buy	664,000 +214,000	+48%	+$7.49M	﹤0.01%	461
2020 Q2	$21.6M	Buy	+450,000	New	+$17.3M	0.01%	429

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors's ZNTL Position: Q4 2023 in Review

Capital World Investors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 683,000 shares — an estimated $13.7M sold.

Capital World Investors first reported a position in ZNTL in Q2 2020 and held it in 14 quarters. The position peaked at $57.4M in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

Capital World Investors reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Capital World Investors sold 683,000 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $13.7M.
Capital World Investors first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Capital World Investors's Zentalis Pharmaceuticals position peaked at $57.4M in Q4 2021.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Capital World Investors's 13F filing for Q4 2023, filed 13 Feb 2024.